

# ISO/TR 22019:2019-05 (E)

## Nanotechnologies - Considerations for performing toxicokinetic studies with nanomaterials

---

<b>Contents</b>	<b>Page</b>
Foreword .....	iv
Introduction .....	v
<b>1 Scope</b> .....	<b>1</b>
<b>2 Normative references</b> .....	<b>1</b>
<b>3 Terms and definitions</b> .....	<b>1</b>
<b>4 Abbreviations</b> .....	<b>3</b>
<b>5 Importance of toxicokinetic information for risk assessment of nanomaterials</b> .....	<b>3</b>
5.1 General .....	3
5.2 Possible use of toxicokinetic information .....	4
5.3 Key toxicokinetic issues for nanomaterials .....	5
<b>6 Factors influencing the toxicokinetics of nanomaterials</b> .....	<b>5</b>
6.1 Dissolution rate .....	5
6.2 Physical chemical properties determinant for toxicokinetic behavior .....	6
<b>7 Analytical challenges</b> .....	<b>10</b>
7.1 General .....	10
7.2 Analysis of element .....	10
7.3 Analysis of element radiolabel or fluorescence label .....	11
7.4 Determination of particles .....	12
7.5 Limit of detection .....	13
<b>8 Issues relevant for dosing conditions</b> .....	<b>13</b>
8.1 General .....	13
8.2 Dose metrics .....	14
<b>9 Absorption of nanomaterials</b> .....	<b>15</b>
9.1 General .....	15
9.2 Skin .....	15
9.3 Gastrointestinal (GI) tract .....	16
9.4 Respiratory tract .....	18
<b>10 Distribution</b> .....	<b>22</b>
10.1 General .....	22
10.2 Organ distribution .....	22
10.3 Transport across the placenta, BBB and to reproductive organs .....	23
<b>11 Metabolism/degradation</b> .....	<b>24</b>
<b>12 Excretion</b> .....	<b>24</b>
<b>13 Conclusions</b> .....	<b>25</b>
<b>Annex A (informative) Definitions as used in OECD Test Guideline 417:2010</b> .....	<b>29</b>
<b>Annex B (informative) Quantitation methods for nanomaterials, advantages and challenges</b> .....	<b>32</b>
<b>Bibliography</b> .....	<b>39</b>